High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma.
hepatocellular carcinoma
immune
prognosis
ubiquitin conjugate enzyme E2O
Journal
Current medical science
ISSN: 2523-899X
Titre abrégé: Curr Med Sci
Pays: China
ID NLM: 101729993
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
11
01
2022
accepted:
14
03
2022
pubmed:
22
10
2022
medline:
8
3
2023
entrez:
21
10
2022
Statut:
ppublish
Résumé
Ubiquitin conjugate enzyme E2O (UBE2O) is a ubiquitin-conjugating enzyme that has been reported to be involved in tumorigenesis. This study investigated the role of UBE2O in hepatocellular carcinoma (HCC). The expression of UBE2O was detected using qRT-PCR, Western blotting, and immunohistochemical staining. Cell proliferation and Transwell assays were used to detect proliferation, migration, and invasion of HCC cells, respectively. Bioinformatic analysis was performed to analyze the relationship between UBE2O and the clinical features, prognosis, and immune cell infiltration of HCC. UBE2O was significantly over-expressed in HCC tissues. High expression of UBE2O was associated with poor tumor grade and poor prognosis. Functional experiments showed that down-regulation of UBE2O inhibited HCC cell proliferation, migration, and invasion. Co-expression gene analysis and gene set enrichment analysis showed that UBE2O was associated with protein hydrolysis, cell cycle, and cancer-related pathways in HCC. The results of immune analysis revealed that the expression of UBE2O was positively correlated with the immune infiltration and expression of immune-related chemokines of HCC. UBE2O is significantly correlated with the prognosis of HCC and may be a valuable prognostic biomarker for HCC.
Identifiants
pubmed: 36269535
doi: 10.1007/s11596-022-2609-1
pii: 10.1007/s11596-022-2609-1
doi:
Substances chimiques
Ubiquitin
0
UBE2O protein, human
EC 2.3.2.24
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-103Informations de copyright
© 2022. Huazhong University of Science and Technology.
Références
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018,391(10127):1301–1314
doi: 10.1016/S0140-6736(18)30010-2
pubmed: 29307467
Pinter M, Peck-radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther, 2018,48(6):598–609
doi: 10.1111/apt.14913
pubmed: 30039640
pmcid: 6120553
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019,16(10):589–604
doi: 10.1038/s41575-019-0186-y
pubmed: 31439937
pmcid: 6813818
Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol, 2014,109(4):542–553
doi: 10.1038/ajg.2014.11
pubmed: 24513805
pmcid: 4148914
Zhang G, Li R, Deng Y, et al. Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol, 2018,12(5):515–523
doi: 10.1080/17474124.2018.1453806
pubmed: 29543072
Yokota T, Nagai H, Harada H, et al. Identification, tissue expression, and chromosomal position of a novel gene encoding human ubiquitin-conjugating enzyme E2-230k. Gene, 2001,267(1):95–100
doi: 10.1016/S0378-1119(01)00407-3
pubmed: 11311559
Hormaechea-Agulla D, Kim Y, Song M S, et al. New Insights into the Role of E2s in the Pathogenesis of Diseases: Lessons Learned from UBE2O. Mol Cells, 2018,41(3):168–178
pubmed: 29562734
pmcid: 5881090
Lin M, Smith LT, Smiraglia DJ, et al. DNA copy number gains in head and neck squamous cell carcinoma. Oncogene, 2006,25(9):1424–1433
doi: 10.1038/sj.onc.1209166
pubmed: 16247453
Toffoli S, Bar I, Abdel-Sater F, et al. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Breast Cancer Res, 2014,16(6):466
doi: 10.1186/s13058-014-0466-y
pubmed: 25416589
pmcid: 4303204
Vila IK, Yao Y, Kim G, et al. A UBE2O-AMPKalpha2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Cancer Cell, 2017,31(2):208–224
doi: 10.1016/j.ccell.2017.01.003
pubmed: 28162974
pmcid: 5463996
Chen X, Zhang S, Liu C, et al. UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Onco Targets Ther, 2020,13:6191–6202
doi: 10.2147/OTT.S253861
pubmed: 32636643
pmcid: 7334014
Liu X, Ma F, Liu C, et al. UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKalpha2/mTORC1-MYC positive feedback loop. Cell Death Dis, 2020,11(1):10
doi: 10.1038/s41419-019-2194-9
pubmed: 31907353
pmcid: 6944706
Huang Y, Yang X, Lu Y, et al. UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance. Cell Death Differ, 2021,28(2):671–684
doi: 10.1038/s41418-020-00616-8
pubmed: 32901121
Cline MS, Craft B, Swatloski T, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep, 2013,3:2652
doi: 10.1038/srep02652
pubmed: 24084870
pmcid: 3788369
Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res, 2017,77(21):e108–e110
doi: 10.1158/0008-5472.CAN-17-0307
pubmed: 29092952
pmcid: 6042652
Lian Q, Wang S, Zhang G, et al. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics, 2018,16(4):269–275
doi: 10.1016/j.gpb.2018.07.003
pubmed: 30266410
pmcid: 6205074
Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res, 2018,46(D1):D956–D963
doi: 10.1093/nar/gkx1090
pubmed: 29136207
Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics, 2019,35(20):4200–4202
doi: 10.1093/bioinformatics/btz210
pubmed: 30903160
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394–424
doi: 10.3322/caac.21492
pubmed: 30207593
Huang A, Yang XR, Chung WY, et al. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther, 2020,5(1):146
doi: 10.1038/s41392-020-00264-x
pubmed: 32782275
pmcid: 7419547
Zhang X, Zhang J, Bauer A, et al. Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2-230K-mediated monoubiquitination of SMAD6. EMBO J, 2013,32(7):996–1007
doi: 10.1038/emboj.2013.38
pubmed: 23455153
pmcid: 3616286
Hao YH, Doyle JM, Ramanathan S, et al. Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination. Cell, 2013,152(5):1051–1064
doi: 10.1016/j.cell.2013.01.051
pubmed: 23452853
pmcid: 3640276
Zhang X, Zhang J, Zhang L, et al. UBE2O negatively regulates TRAF6-mediated NF-kappaB activation by inhibiting TRAF6 polyubiquitination. Cell Res, 2013,23(3):366–377
doi: 10.1038/cr.2013.21
pubmed: 23381138
pmcid: 3587711
Chew V, Lai L, Pan L, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci USA, 2017,114(29):E5900–E5909
doi: 10.1073/pnas.1706559114
pubmed: 28674001
pmcid: 5530700
Locy H, de Mey S, de Mey W, et al. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol, 2018,9:2909
doi: 10.3389/fimmu.2018.02909
pubmed: 30619273
pmcid: 6297829
Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol, 2007,25(18):2586–2593
doi: 10.1200/JCO.2006.09.4565
pubmed: 17577038
Zhou G, Sprengers D, Boor PPC, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology, 2017,153(4):1107–1119.e10
doi: 10.1053/j.gastro.2017.06.017
pubmed: 28648905
Zhu M, Xu W, Wei C, et al. CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis. Cell Death Dis, 2019,10(11):796
doi: 10.1038/s41419-019-1966-6
pubmed: 31641099
pmcid: 6805940
Salem A, Alotaibi M, Mroueh R, et al. CCR7 as a therapeutic target in Cancer. Biochim Biophys Acta Rev Cancer, 2021,1875(1):188499
doi: 10.1016/j.bbcan.2020.188499
pubmed: 33385485
Lin T, Lin Z, Mai P, et al. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. Aging (Albany NY), 2021,13(8):11786–11807
doi: 10.18632/aging.202876
pubmed: 33878734
Wang W, Huang P, Zhang L, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci, 2013,104(11):1523–1531
doi: 10.1111/cas.12279
pubmed: 24033560
pmcid: 7656557